NIH finds significant tumor regression

NIH finds significant tumor regression

NIH finds significant tumor regression

Hospital patient with intravenous IV drip

The scientists found that intravenous administration of the vaccine increased the number of cytotoxic T cells capable of infiltrating and attacking tumor cells and engaged the innate immune system by inducing type I interferon.

NIH scientists find that IV administration improves tumor-fighting activity.

An experimental therapeutic cancer vaccine elicited two distinct and desirable immune system responses that led to significant tumor regression in mice. That’s according to a new study published in the journal Cellreported researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

According to research findings, intravenous (IV) administration of the vaccine increased the number of cytotoxic T cells capable of infiltrating and attacking tumor cells and engaged the innate immune system by inducing type I interferon. The innate immune response modified the tumor microenvironment, counteracting suppressive forces that would otherwise reduce T-cell activity. No modification of the tumor microenvironment was found in mice that received the vaccine by subcutaneous administration (ie, injection with a needle into the skin).

T lymphocyte stained scanning micrograph

Colored scanning electron micrograph of T lymphocytes. Credit: NIAID

Dubbed “vax-innate” by the scientific team, this approach achieves an important goal in the search for more effective cancer immunotherapy vaccines. The study shows that the IV vaccine enables and enhances T-cell immunity by overcoming tumor-induced immunosuppressive activity. According to the researchers, the vaccine candidate could also be given intravenously to people who have already received tumor-specific T cells as therapy. It could also improve tumor control by increasing the number of T cells and changing the tumor microenvironment so that they function better, the researchers note.

SNAPvax, the name of the experimental vaccine, was developed by Robert Seder, MD, and colleagues at the NIAID Vaccine Research Center (VRC) along with collaborators at Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland. Vaccitech has announced plans to advance the SNAPvax platform for use in the treatment of human papillomavirus (HPV)-related cancers in 2023.

Reference: “Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment” Faezzah Baharom, Ramiro A. Ramirez-Valdez, Ahad Khalilnezhad, Shabnam Khalilnezhad, Marlon Dillon, Dalton Hermans, Sloane Fussell, Kennedy KS Tobin, Charles-Antoine Dutertre, Geoffrey M. Lynn, Sören Müller , Florent Ginhoux, Andrew S. Ishizuka and Robert A. Seder, 26 Oct 2022, Cell.
DOI: 10.1016/j.cell.2022.10.006



title_words_as_hashtags]

Leave a Comment

Your email address will not be published. Required fields are marked *